THE CANCER TREATMENT AND RESEARCH TRUST CIO
Support research in medical oncology.
Financial health, per its FY2024 accounts
The accounts state that unrestricted reserves stood at £1,204,178 at year-end, which the trustees confirm exceeds their stated policy target of £350,000. The charity reported a net income increase to £359,949 for the year, driven by higher donations and investment income, while total expenditure decreased to £142,202. The trustees consider the charity to be a going concern with sufficient resources to meet obligations for at least the next 12 months.
What the accounts disclose
“It is the policy of CTRT to hold £350,000 in reserve in addition to the costs associated with any committed research projects for this purpose to ensure we can continue operation for up to 3 years and fulfil our commitments until their completion.” — page 6
Structured financials (annual return, FY ending 31/12/2024)
Trustees
- Professor Michael Julian Seckl PhDchair
- Dr Anand Sharma
- Dr David James Pinato
- Dr Ehsan Ghorani
- Glen Williams
- Kirandeep Kaur Grewal
- PROFESSOR GORDON JOHN SAMPSON RUSTIN
- Professor PAUL DANIEL NATHAN
- Russell John Hallam
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/12/2024 | £502k | £142k |
| 31/12/2023 | £180k | £223k |
| 31/12/2022 | £382k | £203k |
| 31/12/2021 | £0 | £0 |
Common questions
Is THE CANCER TREATMENT AND RESEARCH TRUST CIO financially healthy?
Per its FY2024 accounts: The accounts state that unrestricted reserves stood at £1,204,178 at year-end, which the trustees confirm exceeds their stated policy target of £350,000. The charity reported a net income increase to £359,949 for the year, driven by higher donations and investment income, while total expenditure decreased to £142,202. The trustees consider the charity to be a going concern with sufficient resources to meet obligations for at least the next 12 months. Its FY2024 accounts were independently examined.
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| THE BRITISH DIABETIC ASSOCIATION | 1 | £1.2m |
| BRITISH HEART FOUNDATION | 1 | £600k |
| Arthritis UK | 1 | £316k |
| Vivensa Foundation | 1 | £114k |
| NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH CCR) | 1 | £101k |
| THE HEALTH FOUNDATION | 1 | £100k |
| PROSTATE CANCER UK | 1 | £76k |
| THE JEAN SHANKS FOUNDATION | 1 | £25k |
Charities like this
- THE BIG C APPEAL LIMITED
- CANCER RESEARCH WALES
- CANCER CARE AND HAEMATOLOGY FUND
- STOCKPORT NHS FOUNDATION TRUST GENERAL FUND
- THE BRITISH FRIENDS OF ZICHRON MENACHEM
- CANCER RESEARCH AND GENETICS UK
Side by side with its peers
| Charity | Income | Top pay band | Staff >£60k | Reserves vs policy | Fundraising cost | Going concern |
|---|---|---|---|---|---|---|
| THE CANCER TREATMENT AND RESEARCH TRUST CIO | £502k | — | 0 | above | — | no doubt |
| THE BIG C APPEAL LIMITED | £3.2m | £130,001 - £140,000 | — | unclear | — | no doubt |
| CANCER RESEARCH WALES | £5.9m | — | — | unclear | — | no doubt |
| CANCER CARE AND HAEMATOLOGY FUND | £108k | — | 0 | unclear | — | no doubt |
| STOCKPORT NHS FOUNDATION TRUST GENERAL FUND | £930k | — | 0 | above | — | no doubt |
| THE BRITISH FRIENDS OF ZICHRON MENACHEM | £152k | — | 0 | unclear | — | no doubt |